Phathom Pharmaceuticals Reports Strong Preliminary 2025 Results, Targets H2 2026 Operating Profitability
PHAT has more than doubled off its 52-week low of $2.21.
Summary
Phathom Pharmaceuticals announced robust preliminary financial results for Q4 and full year 2025, highlighted by strong revenue growth and a significant commercial milestone for VOQUEZNA®, alongside a projected path to operating profitability by the second half of 2026.
Key Events · Earnings and Guidance · PHAT
-
Preliminary Q4 and Full Year 2025 Financial Results
Phathom Pharmaceuticals reported preliminary net revenues of $57M-$58M for Q4 2025 and $174.5M-$175.5M for the full year 2025, demonstrating strong commercial performance.
-
VOQUEZNA® Reaches 1 Million Prescriptions
During Q4 2025, the company surpassed one million prescriptions dispensed for its VOQUEZNA® products in the United States since their launch, indicating significant market adoption.
-
Projected Operating Profitability by H2 2026
Management anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation, signaling a positive financial outlook and potential for sustainable growth.
-
Strong Cash Position
The company ended 2025 with approximately $130 million in cash and cash equivalents, with a net cash usage of only $6 million in Q4 2025, providing a solid financial runway.
Analysis · PHAT · Life Sciences
Phathom Pharmaceuticals' preliminary financial results for 2025 indicate strong commercial momentum, with full-year net revenues reaching approximately $175 million. The company also achieved a significant milestone, surpassing one million prescriptions for its VOQUEZNA® products since launch. Crucially, management anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation. This outlook, combined with a healthy cash balance of approximately $130 million and a low quarterly cash burn, provides a strong positive signal for a life sciences company, suggesting a solid financial trajectory and reduced reliance on future capital raises. The stock is currently trading near its 52-week high, reflecting market optimism that these results and future guidance may reinforce.
At the time of this filing, PHAT was trading at $18.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.21 to $18.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.